Pharmaceuticals

SOTIO Biotech Signs Research and License Agreement with Biocytogen for Development of Next-Generation Antibody-Drug Conjugates

bexib
By bexib 0 Min Read

The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Construction confidence declined in July
Next Article Rakkar Digital Appointed Custodian for Thailand’s Largest Cryptocurrency Exchange Bitkub
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Calculated risk: Friday: Retail sales, industrial production
Economy
Renaissance vs. ASNOA Insurance – Which agent network is best for you?
Insurance
Only 40% of financial institutions are satisfied with cloud investing
Banking
Citizen digital tools provide an intuitive experience
Banking